The in vitro antimicrobial activity of an oral penem, WY-49605, was compared with those of six other oral antimicrobial agents against 598 bacterial isolates representing 51 different species. WY-49605 exhibited good activity against most gram-positive bacteria and members of the family Enterobacteriaceae. It had little activity against nonfermenting gram-negative bacilli, Enterobacter spp., Serratia spp., enterococci, Staphylococcus haemolyticus, and methicillin-resistant Staphylococcus aureus. Its activity was unaffected by the ␤-lactamases of Neisseria gonorrhoeae, Haemophilus influenzae, and staphylococci. Disk diffusion susceptibility tests were performed with 5-, 10-, 15-, and 30-g WY-49605 disks. The 5-g disk is recommended, with tentative breakpoints of >16 mm for susceptibility (MIC, <2.0 g/ml) and <12 mm for resistance (MIC, >8.0 g/ml). SY5555, is an orally administered penem that exhibits a broad in vitro antibacterial spectrum against both anaerobic and aerobic bacteria (1, 4-6). It has also been shown to be highly resistant to the actions of a variety of ␤-lactamase enzymes (1, 4).
WY-49605 (previously SUN5555, SY5555, or ALP-201) is an orally administered penem that exhibits a broad in vitro antibacterial spectrum against both anaerobic and aerobic bacteria (1, (4) (5) (6) . It has also been shown to be highly resistant to the actions of a variety of ␤-lactamase enzymes (1, 4) .
In this report, we describe the results of two separate studies. The first study compared the in vitro antibacterial activity of WY-49605 with those of six other oral antibiotics currently available in the United States against a wide range of bacterial isolates. A second study determined the optimal disk content of WY-49605 for disk diffusion susceptibility testing.
MATERIALS AND METHODS
In the first study, 598 stock cultures that had been derived from clinical specimens over the past 15 years were selected to represent the 51 different species that are listed in Table 1 . WY-49605 was provided as a standardized powder by Wyeth-Ayerst Research, Philadelphia, Pa. The drugs used for comparison, amoxicillin, amoxicillin-clavulanate, cefaclor, cefuroxime, cefixime, and ciprofloxacin, were procured from their respective U.S. manufacturers. Susceptibility tests were performed by the broth microdilution method outlined by the National Committee for Clinical Laboratory Standards (NCCLS) (2) . The antibiotic concentrations tested were serial twofold dilutions ranging from 16 to 0.03 g/ml for all drugs except ciprofloxacin, which was tested at concentrations of from 4.0 to 0.008 g/ml.
In the second study, 490 bacterial isolates representing 32 different species were selected from the first culture collection for which there was a wide range of WY-49605 MICs. The week before the second study was initiated, filter paper disks were prepared at the Clinical Microbiology Institute to contain WY-49605 at 110% of the following potencies: 5, 10, 15, and 30 g. The compound has been shown to be stable for up to 2 years at room temperature (7), and there was no change in zone diameters with control strains for the duration of the study. Commercially prepared 30-g ceftriaxone disks (lot no. 204657; B-D Microbiology Systems) were also tested for control purposes. Disk diffusion susceptibility tests were performed with all five disks as outlined by NCCLS (3). Broth microdilution susceptibility tests were performed simultaneously with both WY-49605 (32 to 0.016 g/ml) and ceftriaxone (128 to 0.06 g/ml) as outlined by NCCLS (3). For Neisseria gonorrhoeae and Haemophilus influenzae, WY-49605 MICs were determined by the agar dilution methods outlined by NCCLS (3) and were compared only with those of amoxicillin-clavulanic acid.
RESULTS AND DISCUSSION
Comparative study. Table 1 summarizes the in vitro susceptibility data for WY-49605 in comparison with those for six other oral antimicrobial agents. On the basis of preliminary pharmacokinetic data, with the clinical formula an oral dose containing 150 mg of WY-49605 should give peak concentrations in plasma of about 8.0 g of WY-49605 per ml (7). Thus, 2.0 g/ml was tentatively selected as the susceptibility breakpoint for WY-49605. All 30 isolates of Neisseria gonorrhoeae were susceptible to WY-49605, although the MICs for ␤-lactamase-negative, penicillin-resistant strains were generally fourfold higher than those for the other strains. Ampicillinsusceptible and ␤-lactamase-producing Haemophilus influenzae strains were susceptible to WY-49605, but only half of the ␤-lactamase-negative, ampicillin-resistant strains were inhibited by 2.0 g of WY-49605 per ml. Likewise, methicillinsusceptible Staphylococcus aureus strains were highly susceptible to WY-49605, but only 60% of methicillin-resistant Staphylococcus aureus strains were susceptible to 2.0 g/ml. Those data support the ␤-lactamase stability of WY-49605 (1, 4), but they also indicate that its activity is reduced by the penicillin-binding protein alterations, accounting for the resistance to penicillin, ampicillin, and methicillin by those three organisms, respectively.
Ciprofloxacin was the most active of the test drugs against members of the family Enterobacteriaceae. WY-49605 had good activity against most enteric bacilli other than Enterobacter spp., Serratia spp., and Citrobacter freundii. However, it was more active than the other ␤-lactam compounds against Citrobacter freundii and most Enterobacter spp. Against the other enteric species, WY-49605 and cefixime were the most active ␤-lactams tested. WY-49605 was more active than cefixime against Hafnia alvei and Morganella morganii, and cefixime was more active than WY-49605 against Providencia spp. and Proteus spp. Like the other ␤-lactams tested, WY-49605 had no appreciable activity against nonfermenting gramnegative bacilli.
With the exception of some Enterococcus spp., Staphylococcus haemolyticus, and methicillin-resistant Staphylococcus au- These errors persisted when the strains were retested. No major errors (false resistant) and 57 (12%) minor discrepancies were found. Considering the unusually high prevalence of antibiotic-resistant strains in this challenge collection, these error rates were not entirely unexpected.
For analyses of the WY-49605 data, MIC breakpoints of Յ2.0 g/ml for susceptibility and Ն8.0 g/ml for resistance were used. For the WY-49605 disks of each potency, the inhibitory zone diameter breakpoints were calculated and then adjusted to minimize interpretive discrepancies. The regression analyses were limited to those strains for which WY-49605 MICs were in the range of 0.5 to 32 g/ml to avoid the parabolic skewing caused by the more susceptible strains.
There were eight very major discrepancies (five Proteus mirabilis, two Proteus vulgaris, and 1 Providencia rettgeri strain) with all four disks of each potency, and these were not resolved on retesting. Three additional isolates gave very major errors with the 30-g disk. The calculated zone diameter breakpoints for all four disks of each potency and the resulting error rates are summarized in Table 2 . The major error rate was the same (0.4%) with all disks of each potency, but the minor error rate was somewhat lower (6.0%) with the 5-g disk than with the other disks (7.2 to 7.6%). The organisms giving minor discrepancies were distributed among 11 different species and included 5 of 10 Morganella morganii and 5 of 10 Proteus mirabilis strains. On the basis of these data, we recommend the use of the 5-g disk, with breakpoints of Յ12 mm for resistance and Ն16 mm for susceptibility (Fig. 1) . The disk potency and breakpoints should remain tentative until subsequent pharmacokinetic and clinical data are available to support (or refute) the 2.0-g/ml MIC breakpoint for susceptibility and until the present data are confirmed with commercially prepared disks. a y ϭ log 2 ϩ 9 MIC (in micrograms per milliliter) and x is the diameter of the zone of inhibition (in millimeters). Strains for which MICs were Յ0.25 g/ml were excluded in order to avoid the parabolic portions of the regression curve. (2) . Since a breakpoint for susceptibility has not yet been established for WY-49605, the percentage of isolates inhibited by Յ2.0 g/ml is noted parenthetically.
c Amox-clav, amoxicillin plus clavulanic acid (2:1 ratio; expressed as micrograms of amoxicillin in the combination). d Includes Pseudomonas cepacia (n ϭ 5), Pseudomonas fluorescens (n ϭ 6), Pseudomonas putida (n ϭ 4), and Pseudomonas stutzeri (n ϭ 5). e Includes Salmonella enteritidis (n ϭ 10) and Salmonella typhi (n ϭ 5). 
